Braftovi Capsule
Product Images NDC 70255-025

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Braftovi (NDC 70255-025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Array Biopharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Braftovi 01)

Chemical structure of Encorafenib, the active ingredient in BRAFTOVI capsules. The diagram depicts the arrangement of atoms and bonds representing the molecular structure of Encorafenib.*

FDA Label Image

Figure 1 (Braftovi 02)

A Kaplan-Meier survival curve chart comparing the probability of progression-free survival over 26 months between two treatment groups: BRAFTOVI (encorafenib) combined with binimetinib, and vemurafenib. The chart includes a time axis in months and a vertical axis showing progression-free survival probability, with accompanying patient numbers at risk for each group across time points.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Carton)

This Kaplan-Meier survival curve illustrates the probability of survival over 22 months for patients treated with BRAFTOVI (Encorafenib) plus cetuximab versus a control group. The graph shows higher survival probability in the BRAFTOVI plus cetuximab group compared to control, with the number of patients at risk indicated below the timeline.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Carton)

BRAFTOVI 75 mg capsules label showing the product name, active ingredient Encorafenib, and dosage strength. The label indicates 90 capsules in the package, with distribution by Array BioPharma Inc., a subsidiary of Pfizer. Storage instructions and barcode are also visible, along with an imprint area on the right side.*

FDA Label Image

Braftovi 05

Label for BRAFTOVI (encorafenib) capsules 75 mg, an oral prescription drug by Array BioPharma Inc. The packaging indicates it contains 2 bottles with 90 capsules each. The label includes dosage strength prominently and storage instructions. It is marked Rx only and includes the NDC 70255-025-01.*

FDA Label Image

Braftovi 06

Label for BRAFTOVI (encorafenib) capsules, 75 mg strength, oral dosage form. The label shows storage instructions, usage warnings, and manufacturer information for Array BioPharma Inc. It indicates a sample bottle of 60 capsules not for sale, with printed barcodes and a QR code on a white and black background.*

FDA Label Image

Braftovi 07

Label for BRAFTOVI (encorafenib) capsules, 75 mg strength, oral dosage form. The label states 90 capsules, marked as a sample and not for sale. It is distributed by Array BioPharma Inc., a Pfizer subsidiary, made in France. Storage instructions and packaging details are included, with a barcode and NDC 70255-025 visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.